Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “Pfizer”

A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC)Completed
NCT01920061Phase 1Updated Sep 13, 2022
Sponsor: Pfizer
Neoplasm
United States, Canada, Italy, Spain, United Kingdom
Single-dose PK Study of Ceftazidime-Avibactam In Hospitalized Children Receiving Systemic Antibiotics for Nosocomial PneumoniaTerminated
NCT04040621Phase 1Updated Sep 9, 2022
Sponsor: Pfizer
Hospitalized Children With Suspected or Confirmed Nosocomial Pneumonia
China, Taiwan
Confirming The Sitaxsentan Dose In Patients Undergoing Heart SurgeryCompleted
NCT00838383Phase 2Updated Sep 8, 2022
Sponsor: Pfizer
Cardiac Surgery Subjects · Subjects Undergoing CABG and/or Cardiac Valve Replacement
United States
A First-In-Human Study of the Study Medicine, Called PF-07291177, in Healthy Adult ParticipantsWithdrawn
NCT05434091Phase 1Updated Sep 7, 2022
Sponsor: Pfizer
Healthy Participants
Brief Intervention Study for Quitting SmokingTerminated
NCT01589211NAUpdated Sep 6, 2022
Sponsor: Heidelberg University
Smoking · Tobacco Use Cessation · Smoking Cessation
Germany
Palbociclib With Everolimus + Exemestane In BCCompleted
NCT02871791Phase 1, Phase 2Updated Aug 29, 2022
Sponsor: Dana-Farber Cancer Institute
Human Epidermal Growth Factor 2 Negative Carcinoma of Breast · Hormone Receptor (HR)-Positive Breast Cancer
United States
Efficacy of Celecoxib vs Placebo to Prevent Pain in a Paced WalkCompleted
NCT00194090Phase 4Updated Aug 26, 2022
Sponsor: University Hospitals Cleveland Medical Center
Knee Osteoarthritis
United States
Study To Assess Efficacy, Safety, Tolerability And Pharmacokinetics Of PF-07038124 Ointment In Participants With Atopic Dermatitis Or Plaque PsoriasisCompleted
NCT04664153Phase 2Updated Aug 26, 2022
Sponsor: Pfizer
Atopic Dermatitis · Plaque Psoriasis
United States, Australia, Canada, Poland
Open-Label Extension and Safety Study of TalazoparibCompleted
NCT02921919Phase 2Updated Aug 24, 2022
Sponsor: Pfizer
Cancer
United States, Canada, France, Germany, Hungary +4 more
Endothelial Function in Patients With Pulmonary Arterial HypertensionCompleted
NCT01317134NAUpdated Aug 11, 2022
Sponsor: Universitätsklinikum Hamburg-Eppendorf
Hypertension, Pulmonary · Pulmonary Arterial Hypertension · Pathophysiology · Genetics
Germany
Dalteparin and Sunitinib Malate as First-Line Therapy in Treating Patients With Kidney Cancer That is Metastatic or Cannot Be Removed by SurgeryCompleted
NCT01061411Phase 1Updated Aug 5, 2022
Sponsor: Roswell Park Cancer Institute
Clear Cell Sarcoma of the Kidney · Recurrent Renal Cell Carcinoma · Stage III Renal Cell Cancer · Stage IV Renal Cell Cancer
United States, Netherlands
Optimizing Pembrolizumab Therapy With Timing and Intensification With AxitinibWithdrawn
NCT05263609Phase 2Updated Aug 2, 2022
Sponsor: University of Oklahoma
Renal Cell Cancer
Patient-centered Communication About Healthy Weight in Early Breast CancerCompleted
NCT04504201N/AUpdated Jul 29, 2022
Sponsor: UNC Lineberger Comprehensive Cancer Center
Breast Cancer
United States
Palbociclib In Combination With Letrozole As Treatment Of Post-Menopausal Women With HR+, HER2- Advanced Breast CancerCompleted
NCT02679755Phase 4Updated Jul 27, 2022
Sponsor: Pfizer
Breast Cancer
Australia, India
Management of Tobacco Treatment Intervention in Reducing Surgical Complications in Patients With Newly Diagnosed Lung Cancer Who Smoke CigarettesTerminated
NCT02856581Phase 3Updated Jul 27, 2022
Sponsor: Alliance for Clinical Trials in Oncology
Lung Carcinoma
United States
Study to Compare Oral PF-06651600, PF-06700841 and Placebo in Subjects With Moderate to Severe Ulcerative ColitisCompleted
NCT02958865Phase 2Updated Jul 21, 2022
Sponsor: Pfizer
Ulcerative Colitis
United States, Austria, Bulgaria, Czechia, Denmark +14 more
Study of Multiple Oral Doses of PF-06835919 in Healthy Adult Japanese ParticipantsCompleted
NCT04427917Phase 1Updated Jul 21, 2022
Sponsor: Pfizer
Healthy
Belgium
Response of Children With Atopic Dermatitis (Eczema) to EucrisaCompleted
NCT04023084Phase 4Updated Jul 19, 2022
Sponsor: Ann & Robert H Lurie Children's Hospital of Chicago
Atopic Dermatitis · Eczema
United States
Bosutinib Treatment Extension Study Only For Subjects With Chronic Myeloid Leukemia (CML) Who Have Previously Participated In Bosutinib Studies B1871006 Or B1871008Completed
NCT01903733NAUpdated Jul 19, 2022
Sponsor: Pfizer
Chronic Myeloid Leukemia
United States, Argentina, Australia, Belgium, Brazil +24 more
Assessment of the Prevalence of TTR Amyloid Neuropathy in a Population of Patients With Neuropathy of Unknown AetiologyCompleted
NCT03190577NAUpdated Jul 14, 2022
Sponsor: Nantes University Hospital
Familial Amyloid Neuropathy · Transthyretin Amyloidosis
France
Study Of Single And Multiple Ascending Doses Of PF-07054894 In Healthy Adult ParticipantsCompleted
NCT04388878Phase 1Updated Jul 12, 2022
Sponsor: Pfizer
Healthy
Belgium
A Study of Marstacimab to Compare Prefilled Pen (PFP) Device to Prefilled Syringe (PFS) DeviceTerminated
NCT04832139Phase 1Updated Jul 11, 2022
Sponsor: Pfizer
Healthy Volunteers
Belgium
Safety and Immunogenicity of 20vPnC Coadministered With SIIV in Adults ≥65 Years of AgeCompleted
NCT04526574Phase 3Updated Jul 8, 2022
Sponsor: Pfizer
Pneumococcal Disease
United States
Study of Abrocitinib Compared With Dupilumab in Adults With Moderate to Severe Atopic Dermatitis on Background Topical TherapyCompleted
NCT04345367Phase 3Updated Jul 8, 2022
Sponsor: Pfizer
Atopic Dermatitis
United States, Australia, Bulgaria, Canada, Chile +10 more
Multicenter Study of Peritransplantation Immunosuppression for Mismatched Hematopoietic Cell Transplantation After Reduced Intensity ConditioningTerminated
NCT01582048Phase 2Updated Jul 5, 2022
Sponsor: Prof. Dr. med. Wolfgang Bethge
Patients Receiving Mismatched Allogeneic HCT
Germany

Previous page Next page